Literature DB >> 17363498

p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3.

Ronald Pak Cheung Wong1, Wing Pui Tsang, Pui Yee Chau, Ngai Na Co, Tsun Yee Tsang, Tim Tak Kwok.   

Abstract

Development of drug resistance is one of the major obstacles in cancer chemotherapy. The molecular mechanism leading to drug resistance is still not fully understood. A10A cells, a doxorubicin-resistant subline of human squamous cell carcinoma A431 cells, showed cross-resistance to methotrexate and also resistance to the drug-induced apoptosis. The cells also showed overexpression of a mutated form of p53, p53-R273H (Arg to His at codon 273), and down-regulation of procaspase-3. Knockdown of p53-R273H by p53 small interfering RNA in A431 cells increased procaspase-3 level and sensitized the cells to drug-induced apoptosis. On the other hand, transfection of p53-R273H into p53 null human osteosarcoma Saos-2 cells down-regulated procaspase-3 level and induced resistance to the drug toxicity and drug-induced apoptosis. The results support the idea that p53-R273H may gain new functions in induction of drug resistance and impairment in drug-induced apoptosis through down-regulation of procaspase-3 level. The study sheds new light on the understanding of the gain of function and drug resistance mechanisms associated with mutant p53.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363498     DOI: 10.1158/1535-7163.MCT-06-0336

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  30 in total

Review 1.  Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal.

Authors:  Suoyuan Li; Wei Sun; Hongsheng Wang; Dongqing Zuo; Yingqi Hua; Zhengdong Cai
Journal:  Tumour Biol       Date:  2015-02-11

Review 2.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

Review 3.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

4.  Cyclopentenyl cytosine induces senescence in breast cancer cells through the nucleolar stress response and activation of p53.

Authors:  Min Huang; Patrick Whang; Patrick Lewicki; Beverly S Mitchell
Journal:  Mol Pharmacol       Date:  2011-04-04       Impact factor: 4.436

5.  p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.

Authors:  Luciana P Rangel; Giulia D S Ferretti; Caroline L Costa; Sarah M M V Andrade; Renato S Carvalho; Danielly C F Costa; Jerson L Silva
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

6.  Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9.

Authors:  Jacqueline L Y Chee; Suzan Saidin; David P Lane; Sai Mun Leong; Jacqueline E Noll; Paul M Neilsen; Yi Ting Phua; Hani Gabra; Tit Meng Lim
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

7.  Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.

Authors:  Xiang Wang; Jin-xiu Chen; Yan-hui Liu; Chao You; Qing Mao
Journal:  Neurol Sci       Date:  2012-12-08       Impact factor: 3.307

8.  PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Authors:  Yunqing Li; Fadila Guessous; Sherwin Kwon; Manish Kumar; Opeyemi Ibidapo; Lauren Fuller; Elizabeth Johnson; Bachchu Lal; Isa Hussaini; Yongde Bao; John Laterra; David Schiff; Roger Abounader
Journal:  Cancer Res       Date:  2008-03-15       Impact factor: 12.701

Review 9.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

Review 10.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.